Current Report Filing (8-k)
September 27 2021 - 08:11AM
Edgar (US Regulatory)
0001314052 false 0001314052 2021-09-27
2021-09-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
September 27, 2021
ANAVEX LIFE SCIENCES CORP.
(Exact name of registrant as specified in its charter)
Nevada |
001-37606 |
98-0608404 |
(State or
other jurisdiction |
(Commission |
(IRS
Employer |
of
incorporation) |
File
Number) |
Identification
No.) |
51 West 52nd Street
7th Floor
New York,
NY
USA
10019
(Address of
principal executive offices) (Zip Code) |
1-844-689-3939
(Registrant’s telephone number, including area code)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐ |
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR
230.425) |
☐ |
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)) |
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of Each
Class |
|
Trading Symbol |
|
Name of Each Exchange on Which
Registered |
Common Stock, par value $0.001 per share |
|
AVXL |
|
The
Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
¨
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
On September 21, 2021, Anavex Life Sciences Corp., a Nevada
corporation (the “Company”) received an approval
letter from The Nasdaq Stock Market LLC approving the Company’s
application to list the Company’s common stock, par value $0.001
per share (the “Common
Stock”), on the Nasdaq Global Select Market. Shares of the
Company’s Common Stock were previously listed on the Nasdaq Capital
Market. The Company’s Common Stock is expected to begin trading on
the Nasdaq Global Select Market under its current ticker symbol,
“AXVL”, as of market open September 27, 2021.
On September 27, 2021, the Company issued a press release (the
“Press Release”)
announcing the commencement of trading of its Common Stock on the
Nasdaq Global Select Market. A copy of the Press Release is
attached to this Current Report on Form 8-K as Exhibit 99.1 and
incorporated herein by reference.
Item
9.01 |
Financial
Statements and Exhibits. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
ANAVEX LIFE SCIENCES
CORP. |
|
|
|
By: |
/s/Christopher
Missling |
|
|
Name:
Christopher Missling, PhD
Title: Chief Executive Officer |
Date:
September 27, 2021
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Apr 2022 to May 2022
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From May 2021 to May 2022